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Abstract In recent years, many synthetic cannabinoid
(CB) receptor agonists have appeared on the market as
constituents of herbal incense mixtures known as ‘‘spice’’.
Contrary to the declared use, they are perorally consumed
as a replacement for marijuana to get ‘‘high’’. In many
cases, detailed information on the physicochemical and
pharmacological properties of the synthetic compounds
found in spice preparations is lacking. We have now
evaluated a large series of heterocyclic compounds, 1,3-
disubstituted indole and 2-azaindole derivatives known or
assumed to be CB1 receptor agonists, many of which have
previously been identified in forensic samples. The mainly
observed structural variations to circumvent restriction by
law were bioisosteric exchanges of functional groups in
known CB1 agonists. We analyzed the structure-activity
relationships of compounds at human CB1 and CB2
receptors based on affinities obtained in radioligand bind-
ing studies, and determined their efficacy in cAMP accu-
mulation assays. Moreover, we investigated the activities
of the compounds at the orphan G protein-coupled recep-
tors GPR18 and GPR55 both of which are known to
interact with cannabinoids. Most of the investigated com-
pounds behaved as potent full agonists of CB1 and CB2
receptors with affinities in the low nanomolar to sub-
nanomolar concentration range. Some compounds were
moderately potent GPR55 antagonists, while none inter-
acted with GPR18. Most derivatives were predicted to
cross the blood–brain barrier as determined by bioinfor-
matics tools. These data are useful for assessing synthetic
cannabinoids and will be helpful for predicting pharma-
cological properties of novel compounds that appear on the
illicit drug market.
Keywords Synthetic cannabinoid  Structure-activity
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Introduction
Cannabinoid (CB) receptors belong to the large family of
rhodopsin-like class A G-protein-coupled receptors
(GPCRs) [1]. The cannabinoid receptor 1 (CB1) was first
described in 1993 as a major target for the natural product
D9-tetrahydrocannabinol (D9-THC), the main psychoactive
component of the herbal drug marijuana, derived from the
plant Cannabis sativa [2]. The CB1 receptor is predomi-
nantly expressed in cells of the central nervous system,
mediating the main psychoactive effects of D9-THC [3].
CB1 receptor activation is involved in analgesic and anxi-
ety-related reactions, mediates appetite, and is peripherally
involved in motor control and hypotension [4]. The CB1
receptor has long been discussed and tested as a drug target
in metabolic diseases, relating to the fact that stimulation of
CB1 receptors increases food intake, and its blockade
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reduces appetite [5, 6]. A second cannabinoid receptor
(CB2) was subsequently discovered, which is predomi-
nantly expressed in the immune system, for example in the
tonsils and spleen [7, 8], but has recently been described to
be additionally expressed in the brain, mainly in microglia
[9, 10]. CB2 receptors appear to be involved in inflam-
matory processes, and targeting this receptor may be a new
approach to treat inflammatory diseases [11]. Both CB
receptor subtypes display 44 % identity in amino acid
sequences and are coupled to Gi/o proteins [2, 12]. Thus,
activation of the receptors results in inhibition of adenylate
cyclase, leading to reduced intracellular cAMP levels.
In recent decades, a broad range of potent synthetic
CB receptor agonists and antagonists has been developed
due to their potential for the treatment of various dis-
eases including spasticity and neuropathic pain [13, 14].
Natural and synthetic CB1 agonists are widely abused
due to their psychoactive, euphoric and analgesic effects,
e.g., as ingredients of products commercialized as
incense called ‘‘spice’’. Due to this abuse, many of the
synthetic CB agonists found in spice preparations are
now on the list of controlled substances. However, the
drug market is steadily flooded with new synthetic CB
receptor agonists that are not yet subject to control by
the authorities [15].
The main classes of synthetic cannabinoid receptor
agonists can be divided into the following major chemical
classes: classical cannabinoids (dibenzopyrans, i.e., D9-
THC, see Fig. 1), cyclohexyl-substituted phenols (i.e.,
CP55,940, see Fig. 1), naphthoylindoles, and benzoylin-
doles [16–18]. Based on these chemical structures—de-
scribed and characterized in the scientific literature—novel
derivatives have been commercialized via the Internet.
Most of these new compounds consist of at least four
structural components: 1. an indole or indazole core; 2. an
ester, amide or ketone linker; 3. a ring consisting of a
quinolinyl, naphthyl, adamantyl, tetramethylcyclopropyl or
other moiety; 4. a hydrophobic ‘‘side chain’’ attached to the
nitrogen atom of the indole or indazole ring system. They
mainly display bioisosteric exchanges of substructures to
circumvent legal prohibition. The pharmacological profiles
of these compounds are often not known, and, therefore,
forensic consequences for producers, traders and con-
sumers cannot be anticipated since a scientific basis is
lacking.
CB receptors are not the only targets of cannabinoids.
Two ‘‘orphan’’ GPCRs—GPR18 and GPR55—have been
reported to also interact with cannabinoids [11, 19]. ‘‘Or-
phan’’ receptors are characterized by the lacking of an
endogenous ligand; therefore, their (patho-)physiology
remains unclear. GPR18 was reported to be involved in
microglial and endometrial migration processes [20, 21].
GPR55 is a receptor broadly expressed in the brain, partly
co-expressed with both CB-receptors; its endogenous
agonist was proposed to be lysophosphatidylinositol [22–
24]. As the role of these poorly described orphan receptors
remains largely enigmatic, new scaffolds for receptor
ligands are required to further investigate the role of these
receptors in human (patho-)physiology and to study their
potential as drug targets.
In the present study, we investigated a series of com-
pounds—collected by the Institute of Forensic Toxicology
and Medicine, University of Bonn, based on the analysis of
forensic samples—in radioligand binding assays for their
interaction with both CB receptor subtypes, CB1 and CB2.
Subsequently, the compounds were investigated for their
functional properties in cAMP accumulation assays.
Moreover, the potential of potent CB receptor agonists to
cross the blood–brain barrier was estimated in silico. The
compounds were additionally investigated for their ability
to interact with the CB-like orphan receptors GPR18 and
GPR55. The analysis of structure–activity relationships of
the investigated compounds will help in predicting prop-
erties of novel derivatives.
Fig. 1 Structures and affinities of standard CB receptor agonists




All compounds were obtained from Cayman Chemicals
(Ann Arbor, MI, USA). According to the declaration by the
manufacturer [liquid chromatography—tandem mass
spectrometry (LC–MS/MS) data], the purity of all com-
pounds was[95 %. We confirmed the purity in our labo-
ratories by liquid chromatographic—mass spectrometry
(LC–MS) measurements and found it to be[97 % for all
compounds, except for two, RCS-8 (34; 92.3 %) and
MAM-2201-4F-analog (32; 94.5 %). Compounds FUB-
AKB48 (18) and A-834-735 (46) were synthesized in our
laboratory at a multigram-scale and analyzed by LC–MS,
1H nuclear magnetic resonance (NMR) and 13C NMR
spectroscopy (for details, see the supplementary material).
Membrane preparations for CB receptor assays
Membranes of Chinese hamster ovary (CHO) cells
recombinantly expressing the respective human CB
receptor subtype, as described before [25], were prepared
by scratching the cells off the previously frozen cell culture
dishes in ice-cold hypotonic buffer (5 mM Tris-HCl, 2 mM
EDTA, pH 7.4). The cell suspension was homogenized on
ice for 1 min using an Ultra-Turrax (Ika, Higashiosaka,
Japan) followed by further homogenization for 1 min with
a dounce homogenizer, and subsequently spun down for
10 min at 4 C and 1000g. The supernatant was cen-
trifuged for 60 min at 48,000g. The obtained membrane
pellets were resuspended and homogenized in the required
amount of 50 mM Tris-HCl puffer, pH 7.4, to obtain a
protein concentration at 5–7 mg/mL. Aliquots of the
membrane preparation (1 mL each) were stored at -80 C
until being used [25].
Radioligand binding assays at CB1 and CB2
receptors
Competition binding assays were performed using the CB
agonist radioligand [3H](-)-cis-3-[2-hydroxy-4-(1,1-
dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclo-
hexanol (CP55,940, 4, final concentration 0.1 nM; Perkin-
Elmer Life Siences, Rodgan-Ingesheim, Germany) as pre-
viously described [26]. As a source for human CB1 and
CB2 receptors, membrane preparations of the CHO cells
stably expressing the respective receptor subtype were used
(30 lg of protein/well for CB1 and 8 lg of protein/well for
CB2 receptor preparations). Stock solutions of the test
compound were prepared in dimethyl sulfoxide (DMSO).
The final DMSO concentration in the assay was 2.5 %.
After addition of 15 lL of the test compound in DMSO, 60
lL of [3H]CP55,940 solution in assay buffer, and 60 lL of
membrane preparation to 465 lL of assay buffer [50 mM
Tris, 3 mM MgCl2, 0.1 % bovine serum albumine (BSA),
pH 7.4], the suspension was incubated for 2 h at room
temperature. Total binding was determined by adding
DMSO without a test compound. Nonspecific binding was
determined in the presence of 10 lM of unlabeled
CP55,940. Incubation was terminated by rapid filtration
through a GF/C glass fibre filter (Perkin-Elmer, Boston,
MA, USA) presoaked for 0.5 h with 0.3 % aq. poly-
ethyleneimine solution, using a Brandel 96-channel cell
harvester (Brandel, Gaithersburg, MD, USA). The filter
was washed three times with ice-cold washing buffer
(50 mM Tris, 0.1 % BSA, pH 7.4) and then dried for 1.5 h
at 50 C. Radioactivity on the filter was determined in a
liquid scintillation counter (Topcount NXT, Packard/Per-
kin-Elmer, Boston, MA, USA) after 10 h of preincubation
with 50 ll of scintillation cocktail (Multiscint 25, Perkin-
Elmer). Data were obtained in three independent experi-
ments, performed in duplicates. Data were analyzed using
GraphPad Prism Version 4.02 (San Diego, CA, USA). For
the calculation of Ki values, the Cheng-Prusoff equation
and a KD value of 2.4 nM ([
3H]CP55,940 at CB1) and
0.7 nM ([3H]CP55,940 at CB2) were used [26].
cAMP accumulation assays
Inhibition of adenylate cyclase activity was determined in
CHO cells stably expressing the CB1 or the CB2 receptor
subtype, respectively, using a competition binding assay
for cAMP [25]. All details on the reagents and their origins
were described in Ref. [25]. Cells were seeded into a
24-well plate at a density of 200,000 cells/well 24 h before
performing the assays. After the incubation (see below),
the cells were washed with Hank’s buffered saline solution
(HBSS) consisting of NaCl (13 mM), HEPES (20 mM),
glucose (5.5 mM), KCl (5.4 mM), NaHCO3 (4.2 mM),
CaCl22 H2O (1.25 mM), MgSO4 (0.8 mM), MgCl2
(1 mM), KH2PO4 (0.44 mM), and Na2HPO4 (0.34 mM)
dissolved in deionized, autoclaved water. After addition of
190 lL of HBSS per well, cells were incubated for 2 h at
37 C. After this period of time, the phosphodiesterase
inhibitor Ro-20-1724 [4-(3-butoxy-4-methoxybenzyl)-2-
imidazolidinone, Sigma-Aldrich, St. Louis, MO, USA], at a
final concentration of 40 lM dissolved in HBSS, test
compound, and forskolin (final concentration: 10 lM,
Sigma-Aldrich), all dissolved in HBSS containing 10 %
DMSO, were added to each well. The final DMSO con-
centration was 1.9 %. The suspension was incubated for
10 min after the addition of Ro-20-1724, for 5 min after
the addition of test compound, and for another 15 min after
Forensic Toxicol (2016) 34:329–343 331
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adding forskolin. cAMP accumulation was stopped by
removing the supernatant from the cell suspension and
subsequently lyzing the cells with 500 lL of hot lysis
buffer (100 C; 4 mM EDTA, 0.01 % Triton X-100).
Aliquots of 50 lL of cell suspension were transferred to
2.5-mL tubes, into which 30 lL of [3H]cAMP (3 nM) and
40 lL of cAMP-binding protein (50 lg) were added, fol-
lowed by 1 h of incubation at room temperature. The
cAMP binding protein was obtained from bovine adrenal
cortex as previously described [25]. Bound and free radi-
oligands were separated by rapid filtration through a GF/B
glass fibre filter (Perkin-Elmer). Radioactivity on the filter
was determined in a liquid scintillation counter (TRICARB
2900TR, Packard/Perkin-Elmer) after 6 h of preincubation
with 3 mL of scintillation cocktail (LumaSafeplus, Perkin-
Elmer). Data were obtained from three independent
experiments, performed in duplicates.
b-Arrestin assays at GPR55 and GPR18
Recruitment of b-arrestin to the respective receptor was
detected by using b-galactosidase enzyme fragment com-
plementation technology (b-arrestin PathHunterTM assay,
DiscoverX, Fremont, CA, USA) as previously described
[27]. Data were obtained from three independent experi-
ments, performed in duplicates. Data were analyzed using
Graph Pad Prism Version 4.02 (San Diego, CA, USA).
In-silico estimation of drug properties
Properties of compounds were predicted with the program
Stardrop 5.5 (Optibrium, Cambridge, UK) using the
ADME QSAR (quantitative structure-activity relationship)
tool predicting the Lipinski rule of five, oral central ner-
vous system (CNS) scoring profile and intravenous CNS
scoring profile with standard conditions.
Results and discussion
In this study, we investigated the CB receptor binding
affinities and functional properties of three different classes
of compounds structurally related to known CB receptor
agonists. These compounds had been identified in ‘‘spice’’
preparations suspected to be commercialized for drug
abuse (unpublished data).
Binding affinities to CB1 and CB2 receptors
All compounds were investigated in radioligand binding
experiments in CHO cell membrane preparations stably
expressing the human CB1 or CB2 receptor using
[3H]CP55,940 as a radioligand. Ki values are presented in
Table 1. CB1 or CB2 selectivity of compounds was cal-
culated based on the Ki values, and can be found in the
electronic supplementary material (Table S1). All of the
investigated compounds share a common core structure:
(aza)indole. Three different types of linkers between the
(aza)indole ring system and a bulky, lipohilic residue are
observed: an amide, an ester or a shorter carbonyl linker.
The most potent compounds for the CB1 receptor were
found among the ester-linked subgroup [BB-22 (27), PB-22
(24) and 5F-PB-22 (25), NM-2201 (19)] with Ki values
ranging from 0.217 to 0.468 nM. The only exception was
the carbonyl-linked compound EAM-2201 (31), with a
similarly low Ki value of 0.380 nM.
In all three subgroups, compounds with typical
bioisosteric exchanges are found. Three features of the
molecule are varied: the N1-substituent, which was origi-
nally a pentyl moiety in the lead compounds of the JWH
group [13]; in the current compounds, it is fluorinated or
exchanged for a para-fluorobenzyl residue. The effect of
fluorination on binding affinity was moderate: in the nine
examples included in our study, binding affinity for the
CB1 receptor was slightly enhanced for fluorinated com-
pounds [compare MN-18 (8) and 5F-MN-18 (9); THJ (10)
and 5F-THJ (11); APICA (15) and STS-135 (16); SDB-005
(22) and 5F-SDB-005 (23); THJ018 (28) and THJ2201
(29); and AB001 (35) and 5F-AB001 (36)] or slightly
decreased [compare NNEI (4) and 5F-NNEI (5); SDB-006
(12) and 5F-SDB-006 (13); PB-22 (24) and 5F-PB-22
(25)]. Banister et al. [28] investigated the effects of fluo-
rinated compounds and found that although the EC50 value
of the investigated compounds were lower in vitro, this was
not translated to higher in vivo potencies, leading to the
assumption that pharmacokinetic effects play a role [28]. In
their study, they investigated, amongst others, the pairs
UR-144 (37) and XLR-11 (38), PB-22 (24) and 5F-PB-22
(25), and also APICA (15) and STS-135 (16). They per-
formed membrane potential measurements using a fluoro-
metric imaging plate reader (FLIPR) assay kit and
determined slightly higher EC50 values for the compounds
as compared to the radioligand binding data obtained in the
present study. XLR-11-2-fluoropentyl-isomer (39), a
derivative with a 2-fluoropentyl side chain, is the only
compound in this series with a fluorine introduced at
position 2 of the pentyl side chain. In comparison to the
non-fluorinated analogue UR-144 (37), the affinity of 39 at
the CB1 receptor was almost the same, but it was not as
potent as XLR-11 (38), the 5-fluoinated derivative. MAM-
2201-4-fluoropentyl-substituted isomer (32), showed also
slightly higher Ki values than the 5-fluoropentyl derivative
MAM-2201 (30). In this series, only one compound con-
tains of a 5-chloro-substitution: 5Cl-NNEI (6), which dis-
played about five-fold lower affinity for the CB1 receptor
than the unsubstituted derivative NNEI (4). Another
332 Forensic Toxicol (2016) 34:329–343
123
Table 1 Affinities of
investigated compounds at





Ki ± SEM (nM)a
R1 R2 X Human 
CB1
Human CB2
1 Δ9-THC (for structure see Fig. 1) 3.87 ± 0.91 71.6 ± 2.4
2 CP55,940 (for structure see Fig. 1) 1.28 ± 0.44 1.42 ±0.75








Blaazer et al. [33])
5 5F-NNEI CH 3.69 ± 1.97 13.4 ± 1.6





CH 235 ± 15 226 ± 24b
8 MN-18 N 3.86 ± 0.90 3.47 ± 0.89
9 5F-MN-18 N 1.65 ± 0.26 2.50 ± 0.86
10 THJ N 103 ± 25 12.7 ± 4.1
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(5F-AKB48) N 1.94 ± 0.55 0.266 ± 0.041
18 FUB-AKB-48 N 1.06 ± 0.29 0.174 ± 0.018
3-Oxycarbonylindoles and - indazoles (B)
19 NM-2201 CH 0.332 ± 0.107 0.732 ± 0.174
20 FDU-PB-22 CH 1.19 ± 0.39 2.43 ± 0.92



































Banister et al. [28])
26 FUB-PB-22 CH 0.386 ± 0.117 0.478 ± 0.124
27 BB-22 CH 0.217 ± 0.056 0.338 ± 0.045
and -indazoles (C)
28 THJ018 N 5.84 ± 1.32 4.57 ± 0.28
29 THJ2201 N 1.34 ± 0.54 1.32 ± 0.39
30 MAM-2201 CH 1.58 ± 0.76 0.582 ± 0.123
3-Carbonylindoles
31 EAM-2201 CH 0.380 ±0.111 0.371 ± 0.052
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Table 1 continued
36 5F-AB001 CH 12.3 ± 3.0 1.47 ± 1.03
37 UR-144 CH
55.9 ± 6.5


















CH 59.5 ± 16.9 1.83 ± 0.47








Frost et al. [40])









































Banister et al. [36])








Banister et al. [46])
4-fluoropentyl-
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bioisosteric replacement of the 5-fluoropentyl side chain is
a para-fluorobenzyl residue. This variation is observed in
four compounds of the present series [compare: 5F-AKB48
(17) and FUB-AKB48 (18); NM-2201 (19) and FDU-PB-
22 (20); 5F-PB-22 (25) and FUB-PB-22 (26); XLR-11 (38)
and FUB-144 (42)]. The affinity for both CB receptors was
almost identical in three of the four pairs; only FDU-PB-22
(20) was not quite as potent as NM-2201 (19). Thus, a
para-fluorobenzyl residue appears to be an optimal
bioisosteric exchange for obtaining compounds with simi-
larly high affinity as the 5-fluoropentyl-substituted parent
compound.
Other side chains have been introduced at the indole
nitrogen atom. Huffman et al. [13], who established
alkylindoles as cannabinoid receptor ligands, already per-
formed a comprehensive structure-activity relationship
study introducing different side chains. They showed that a
five-carbon side chain is preferred [13]. Thus, pentyl side
chains and their bioisosteric analogs confer high potency
and activity at the CB1 receptor. Whenever the size is
decreased, affinity for the CB1 receptor is largely reduced.
As this structural feature is crucial for high CB1 affinity, it
had previously been modified to design CB2-selective
compounds [29].
Another frequently observed variation is the replace-
ment of the indole core by an indazole ring system. In the
group of compounds with an amide linker (A), it could be
observed that the affinity for the CB1 receptor was quite
similar for indoles and indazoles, while the affinity for the
CB2 receptor was slightly increased in indazole derivatives
[compare NNEI (4) and MN-18 (8); 5F-NNEI (5) and 5F-
MN-18 (9); STS-135 (16) and 5F-APINACA (17)]. In the
group of compounds with an ester linkage (B), the indole
derivative NM-2201 (19) showed lower Ki values at CB1
and CB2 receptors than the corresponding indazole
derivative 5F-SDB-005 (23). In group C compounds con-
taining a keto-group as a linker, XLR-11 (38) and its
indazole analogue FAB-144 (42) displayed almost
identical binding affinities. Thus, a variation of the hete-
rocyclic core from indole to indazole is widely tolerated.
One other common feature of this group of compounds
is the bulky lipophilic residue in position R1. Huffman
et al. [16] introduced mainly naphthyl residues in that
position. A variation of this structural element represents
the introduction of a quinoline found in some compounds
such as THJ (10) and PB-22 (24) [30]. In group A com-
pounds with an amide linker, the introduction of a quino-
line led to 14- and 27-fold higher Ki values at CB1
receptors, respectively [compare MN-18 (8) with THJ (10);
and 5F-MN-18 (9) with 5F-THJ (11)], while the affinity for
CB2 receptors remained unaltered in the low nanomolar
range. In the ester-linked compounds (B), the quinoline-
substituted analogue of NM-2201 (19), 5F-PB-22 (25),
showed comparable affinities for both receptors. FUB-PB-
22 (26) is a quinoline derivative with somewhat higher
affinity at CB1 and CB2 receptors as compared to its ana-
logue FDU-PB-22 (20). The most potent compound in this
series of cannabinoid ligands, BB-22 (27)—sometimes
referred to as QUCHIC—is also a quinoline derivative,
which was first described in illicit drug material in 2013 in
Japan [30]. This compound has a cyclohexylmethyl residue
in position R2, which imitates the length of a pentyl chain
that was previously described to be important for CB
potency [13], and which was beneficial for CB1 receptor
affinity also in a series of magnolol derivatives [31].
Compounds MAM-2201 (30) and EAM-2201 (31) dis-
play substitution of the naphthyl residue, containing a
methyl (MAM-2201 (30) or an ethyl (EAM-2201 (31)
group in position 4 of the naphthyl ring. EAM-2201 (31)
was highly potent at the CB1 receptor with a Ki value of
0.380 nM without preference for any of the CB receptor
subtypes. MAM-2201 (30), which had been described to
cause severe toxicity in the cerebellum of rats [32], was
found to be four times less potent at the CB1 receptor.
The only compound which is not linked in the 1-position
of the naphthyl residue but is linked in the 2-position, 5F-
Table 1 continued 2-Methyl-3- (D)












a Versus 0.1 nM [3H]CP55,940. For the experimental procedures see the section ‘‘Membrane preparations
for CB receptor assays’’. The Ki values are expressed as mean ± standard error of the mean (SEM) of
three to five independent experiments. Literature data are given in brackets for comparison if available.
EC50 values are from functional assays
b Maximal inhibition of radioligand binding: 80 % at 30 lM
c Maximal inhibition of radioligand binding: 73 %
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NNEI-2-naphthyl-isomer (7), was a much weaker CB1
receptor ligand and also showed only partial inhibition of
radioligand binding at the CB2 receptor. NNEI (4), which
was first described by Blaazer et al. [33] in 2011, showed a
pKi value of 8.9 in their binding experiments at the CB1
receptor, which we have now confirmed. The authors also
synthesized a non-fluorinated derivative of compound 7
(5F-NNEI-2-naphthyl-isomer) which displayed a lower pKi
value of 7.2 for the CB1 receptor. The same relation could
be shown in the present study [compare 5F-NNEI (5) and
5F-NNEI-2-naphthyl-isomer (7)]; if the naphthyl residue is
linked in 2-position to the amide, the affinity was decreased
by about 100-fold.
Huffman et al. [13] investigated the effects of substi-
tuting the naphthyl ring by smaller aromatic residues,
which reduced affinity to the CB1 receptor. This could also
be observed for the benzyl-substituted compounds SDB-
006 (12) and 5F-SDB-006 (13) investigated in the present
study. They showed much lower affinity for both CB
receptors as compared to the napthyl-substituted com-
pounds with Ki values in the high nanomolar range. The
phenyl-substituted derivative SDB-006-N-phenyl-analog
(14) displayed even higher Ki values. In group C com-
pounds, RCS-4 (33) and RCS-8 (34) also feature a phenyl
or a benzyl residue. Wiley et al. [34] described that the
substitution in the ortho-position is crucial for high affinity,
which is realized in both compounds. RCS-8 (34), first
described in 2012 in the USA [35], is benzyl-substituted in
position 1 and has a cyclohexylethyl residue in position 2;
it shows weaker affinity for both CB receptors than RCS-4.
RCS-4 and isomers were investigated by Banister et al.
[36] who found that RCS-4 (33) displayed EC50 values of
145 nM for CB1 and 46 nM for CB2. In the present study,
RCS-4 (33) with Ki values of 26.6 nM for CB1 and
2.86 nM for CB2 displayed higher binding affinities.
The aromatic residue R1 may be replaced by a more
bulky lipophilic group, namely an adamantyl or a tetram-
ethylcyclopropyl residue. Comparing the naphthyl deriva-
tives NNEI (4) and 5F-NNEI (5) with the adamantyl
derivatives APICA (15) and STS-135 (16), it can be
observed that CB2 affinity was increased. Also, the
tetramethylcyclopropyl derivatives of group C displayed,
independently of the side-chain variations, a CB2 prefer-
ence. Compounds UR-144 (37), A-796,260 (45),
A-834,735 (46) and XLR-12 (41) were first described by
Frost et al. [29] in the search for selective CB2 agonists.
We could confirm the reported Ki values, but only XLR-12
(41) displayed a 10-fold higher Ki value in our hands as
compared to the literature data. From this group of com-
pounds, some derivatives emerged on the illicit drug
market, mainly in Sweden [37, 38]. FAB-144 (40), the
indazole and 5-fluoropentyl analogue of UR-144 (37),
showed slightly increased affinity for both CB receptors,
and FUB-144 (42), the para-fluorobenzyl derivative dis-
played similar affinity. Also, compound M-144 (47), which
is substituted in position 2 of the indole ring system with a
methyl group, displayed a similar profile. AB-005 (43), a
chimeric compound with the CB2 selectivity-increasing
tetramethylcyclopropyl residue for R1 and N-methyl-2-
piperidinylmethyl substitution as R2 which retains CB1
affinity, was first introduced by Frost et al. in 2010 [29]. A
derivative with an azepane ring (44) appeared on the illicit
drug market, but as we found, it displayed no affinity for
the CB1 receptor at concentrations up to 10 lM. If it should
exert any psychotropic effect, it would not be mediated via
this receptor. At CB2 receptors, a moderate affinity was
observed for 44. A structurally related but more potent
compound is MN-25 (48), which was introduced by Wro-
belenski et al. [39]; it was reported to be abused in previous
years [39].
In summary, almost all investigated compounds showed
high affinity for CB receptors. Some compounds displayed
Ki values in the subnanomolar range and, thus, are many
times more potent than the psychoactive drug D9-THC.
Functional properties of investigated compounds
To investigate the functional properties of the compounds,
cAMP accumulation assays were performed. Both CB
receptors are Gi-coupled receptors, whose activation results
in decreased cAMP levels in the cell. For comparison, the full
agonist CP55,940 and the partial agonist D9-THC were
investigated, and results were normalized to maximal
receptor activation by the full agonist CP55,940 (see Fig. 2).
Compounds were tested at a concentration where maximal
binding was observed, either at 1 lM for the more potent
compounds or at 10 lM for the less potent compounds.
In the utilized recombinant cell lines, D9-THC behaved
as a partial agonist, at both CB1 and CB2 receptors, with
60–70 % activation as compared to the full CB1/CB2
agonist CP55,940 (2). Almost all compounds showed a
high degree of activation of both receptor subtypes.
Exceptions were 3-CAF (21) and AB-005 azepane isomer
(44), which did not activate the CB receptors at all. As both
compounds showed affinity for the CB2 receptor, they may
be characterized as moderately potent CB2-selective
antagonists. The only agonistic compounds with lower
efficacy than D9-THC were NNEI-2-naphthyl isomer (7),
MN-18 (8), XLR-12 (41) and AB005 (43). Most of the
compounds had similar efficacies at both receptor sub-
types; only 5F-APINACA (17) activated CB1 receptor
more efficaciously than CB2.
For the CB2-selective derivative XLR-12 (41), full
concentration response curves were recorded and EC50
values were determined (Fig. 3). It showed a 30-times
lower EC50 value of 0.391 nM at the CB2 receptor than at
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the CB1 receptor; thus, the compound’s preference could
also be observed in the functional assays.
Ki values measured in radioligand binding in many cases
(Table 1) correlated quite well with reported and the EC50
values determined in cAMP accumulation assays (data not
shown). CB2-selectivity of compound XLR-12 (41) could
be confirmed, but in our hands it was lower (only 30-fold,
Fig. 3) than previously reported one (167-fold) [40]. It
should be emphasized that EC50 values depend on receptor
expression levels while radioligand binding data are inde-
pendent of receptor density or G protein expression. They
directly reflect the affinity of compounds for the binding
site on the receptors.
Compounds that activate the CB1 receptor to a compa-
rable extent as D9-THC and that can cross the blood-brain
barrier will likely cause similar psychotropic effects as
D9-THC. Some compounds showed even higher efficacy
than the full agonist CP55,940, including the very potent
compounds EAM-2201 (31), NM-2201 (19) and BB-22
(27). Their toxicity may be much higher than that ofD9-THC
due to their high potency and full efficacy. PB-22 (24), a
CB1/CB2 partial agonist with similar efficacy asD
9-THC but
with higher subnanomolar affinity (Table 1), had previously
been reported to even cause lethal intoxications [41, 42].
In silico prediction of drug properties
As a precondition to achieve psychoactive effects, brain
penetration of the compounds is required. This property
can be determined in animal studies. Alternatively, an in








































































Fig. 2 Functional properties of investigated compounds determined
in cAMP accumulation assays, in the presence of forskolin (10 lM).
Test concentration was 1 lM or 10 lM, depending on the determined
Ki value. The selected concentration corresponds to the concentration
at which a maximal effect was observed. All experiments were
carried out three to five times, each in duplicate. a Compounds 4–18;
b compounds 19–27; c compounds 28–24. All results were normal-
ized to maximal receptor activation by the full agonist CP55,940 (2)
338 Forensic Toxicol (2016) 34:329–343
123
silico prediction based on established data sets can be used
to gain an idea whether a set of compounds is able to cross
the blood-brain barrier. For the investigated compounds,
this was accomplished using the QSAR software Stardrop
5.4 (Optibrium). In Fig. 4, affinities of the investigated
compounds were compared to their lipophilicity, which is
one of the major determinants for crossing biomembranes.
As can be observed, all compounds share a rather high
logP value between 3 and 7. All highly potent compounds
exceeded a logP of 4.5. The standard CB agonists dis-
played similarly high logP values of 6.50 (D9-THC), and
5.36 (CP55,940). The compounds’ potency is not directly
correlated with their lipophilicity (see Fig. 4). Based on
calculations to estimate lipophilicity (logP), topographical
polar surface area and other parameters, a prediction
whether compounds are able to cross the blood-brain bar-
rier is made by the program. The compounds could thus be
divided into two groups, blood-brain barrier-penetrant and
non-penetrant compounds. THJ (10) and 5F-THJ (11), both
of which are 3-(8-quinolinyl)amido-indazoles, were pre-
dicted not to cross the blood-brain barrier. Based on in
silico predictions it is, however, likely that the majority of
the investigated compounds has the ability to cross the
blood-brain barrier.
Effects on the orphan receptors GPR18 and GPR55
The orphan GPCRs GPR18 and GPR55 have been shown
to be targeted by a range of cannabinoid receptor ligands
[19, 29, 43]. Therefore, we investigated whether the
investigated spice constituents also interact with these
cannabinoid-related receptors (Table 2). None of the
compounds was able to activate GPR18 or to inhibit
GPR18 activation up to a concentration of 10 lM. At
GPR55, some compounds were found to be moderate
antagonists, namely, APICA (15) and STS-135 (16) with
IC50 values of 3–5 lM, as well as several compounds
from group C. EAM-2201 (31) was the most potent
GPR55 antagonists of this series with an IC50 value of
1.86 lM. Interestingly, none of the ester compounds
(B) showed any inhibitory effect, and most of the active
compounds were tetramethylcyclopropyl-substituted
derivatives containing the CB2-preferring structure. UR-
144 (37), XLR-11-2-fluoropentyl-isomer (39) and XLR-12
(41), which feature a lipophilic aliphatic or fluoropentyl
side chain, were more potent than A-769,260 (45) or
A-834,735 (46) with a morpholine or tetrahydropyran
substituent, respectively. A typical functional behavior of
cannabinoids at GPR55 can also be observed here:
although all of the identified GPR55 ligands were agonists
at the CB receptors, they showed inhibitory effects at
GPR55. The same had been demonstrated for the CB
agonist CP55,940 (2) as well as other CB receptor ago-
nists [27, 44]. On the other hand, CB1 receptor antago-
nists, such as rimonabant, are agonists of GPR55 [22, 27,
45]. Both receptors, CB1 and GPR55, were reported to be
co-localized in the brain, and receptor heteromerization
has been postulated [23, 24].









CB1: EC50 = 11.7 ± 6.5 nM























Fig. 3 Concentration-dependent inhibition of cAMP accumulation
by XLR-12 (41). All experiments were carried out three to five times,
each in duplicate
pKi CB1































Fig. 4 a Affinities of investigated compounds at the CB1 receptor
plotted against logP values. b Affinities of investigated compounds at
the CB2 receptor plotted against logP values
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Table 2 Activities of test compounds in b-arrestin assays at human GPR55 and GPR18









1 THC – 14.2 [47] 4.61 [47] –
2 CP55,940 – 1.61 [48] – 5.99 [47]
(A) 3-Amidoindoles and -indazoles
4 NNEI [10 (26 %) [10 (30 %) [10 (42 %) [10 (-15 %)
5 5F-NNEI [10 (25 %) [10 (-8 %) [10 (-3 %) [10 (-17 %)
6 5Cl-NNEI [10 (28 %) [10 (5 %) [10 (1 %) [10 (-13 %)
7 5F-NNEI-2-naphthyl-isomer [10 (19 %) [10 (20 %) [10 (9 %) [10 (5 %)
8 MN-18 [10 (27 %) [10 (35 %) [10 (2 %) [10 (37 %)
9 5F-MN-18 [10 (38 %) [10 (-5 %) [10 (-26 %) [10 (23 %)
10 THJ [10 (11 %) [10 (50 %) [10 (4 %) [10 (30 %)
11 5F-THJ [10 (28 %) [10 (10 %) [10 (-17 %) [10 (44 %)
12 SDB-006 [10 (-5 %) [10 (36 %) [10 (-9 %) [10 (22 %)
13 5F-SDB-006 [10 (-3 %) [10 (11 %) [10 (13 %) [10 (-24 %)
14 SDB-006-N-phenyl-analog [10 (20 %) [10 (1 %) [10 (9 %) [10 (-13 %)
15 APICA [10 (11 %) 4.77 ± 1.69 [10 (8 %) [10 (44 %)
16 STS-135 (5F-APICA) [10 (1 %) 3.41 ± 0.47 [10 (-2 %) [10 (30 %)
18 FUB-AKB-48 [10 (-11 %) (83 %) [10 (-27 %) (69 %)
(B) 3-Oxycarbonylindoles and -indazoles
19 NM-2201 [10 (17 %) [10 (23 %) [10 (-8 %) [10 (32 %)
20 FDU-PB-22 [10 (11 %) [10 (30 %) [10 (30 %) [10 (-4 %)
21 3-CAF [10 (26 %) [10 (41 %) [10 (4 %) [10 (10 %)
22 SDB-005 [10 (8 %) [10 (23 %) [10 (15 %) [10 (24 %)
23 5F-SDB-005 [10 (21 %) [10 (47 %) [10 (21 %) [10 (24 %)
24 PB-22 [10 (15 %) [10 (-12 %) [10 (-18 %) [10 (26 %)
25 5F-PB-22 [10 (5 %) [10 (-10 %) [10 (-5 %) [10 (-5 %)
26 FUB-PB-22 [10 (5 %) [10 (24 %) [10 (15 %) [10 (8 %)
27 BB-22 [10 (9 %) [10 (34 %) [10 (2 %) [10 (18 %)
(C) 3-Carbonylindoles and -indazoles
28 THJ018 [10 (6 %) 8.20 ± 2.11 [10 (33 %) [10 (-5 %)
29 THJ2201 [10 (-1 %) [10 (47 %) [10 (18 %) [10 (21 %)
31 EAM-2201 [10 (-24 %) 1.86 ± 0.16 [10 (14 %) [10 (4 %)
32 MAM-2201-4-fluoropentyl-
isomer
[10 (-41 %) 3.07 ± 1.48 n.d. n.d.
35 AB001 [10 (-14 %) *10 (56 %) [10 (-12 %) *10 (62 %)
36 5F-AB001 [10 (19 %) *10 (48 %) [10 (-6 %) *10 (18 %)
37 UR-144 [10 (-5 %) 6.70 ± 1.65 [10 (17 %) [10 (14 %)
39 XLR-11-2-fluoropentyl-isomer [10 (-8 %) 5.69 ± 1.95 [10 (24 %) [10 (29 %)
40 FAB-144 [10 (5 %) *10 (77 %) [10 (2 %) *10 (57 %)
41 XLR-12 [10 (-5 %) 4.56 ± 1.97 [10 (27 %) [10 (13 %)
42 FUB-144 [10 (-3 %) *10 (62 %) [10 (-12 %) *10 (74 %)
43 AB005 [10 (16 %) [10 (39 %) [10 (-38 %) [10 (-2 %)
44 AB005-azepane-isomer [10 (21 %) [10 (18 %) [10 (11 %) [10 (-6 %)
45 A-796,260 [10 (-1 %) 14.3 ± 2.5a [10 (20 %) [10 (-10 %)
46 A-834,735 [10 (8 %) 6.88 ± 1.51a [10 (6 %) [10 (6 %)
(D) 2-Methyl-3-carbonylindole
47 M-144 [10 (-5 %) *10 (86 %) [10 (-7 %) *10 (67 %)
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Conclusions
In conclusion, we determined the binding affinity of a large
number of synthetic compounds suspected to be con-
stituents of spice herbal blends. Our results confirm that the
majority of the investigated compounds behave as highly
potent CB receptor ligands with affinities in the low
nanomolar to subnanomolar concentration range. Further-
more, we could show that they behave as agonists with
high efficacy. In an in silico approach, all except two
derivatives were predicted to cross the blood-brain barrier,
and, therefore, are likely to produce psychoactive effects.
The main structural variations of the compounds represent
typical bioisosteric exchanges altering the structure of the
compounds to circumvent restriction by law, but to retain
the intended psychoactive effects. Knowledge of classical
medicinal chemistry provides, in these cases, powerful
strategies to bypass controlled substances. In our study, we
provide a comprehensive analysis of the structure-activity
relationships of spice constituents including 27 compounds
of previously unknown potency and efficacy. The obtained
data were compared to those of established CB receptor
ligands. In the future, this may help to predict pharmaco-
logical behaviour of novel compounds that appear on the
illicit drug market.
The compounds were further investigated at the CB
receptor-related orphan GPCRs GPR18 and GPR55. While
no interaction with GPR18 was detected, some derivatives
behaved as weak antagonists of GPR55. Because knowl-
edge about these newly discovered orphan receptors is still
very limited, our results contribute to a better understand-
ing of their ligands’ structural requirements. Moreover, we
have identified novel GPR55 antagonists that could be used
as starting points for future optimization.
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